Simile, a startup specializing in synthetic users, has rapidly scaled its valuation to $2 billion, securing $200 million in a Series B funding round just five months after its $100 million Series A. The new financing was led by Greenoaks, with continued support from previous investors including Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures. Notably, CVS Health Ventures is both an investor and a key client, highlighting Simile's traction with prominent customers.

Founded by Stanford PhD graduate Joon Sung Park, Simile creates AI-driven simulated users designed to assist in marketing and product research. Park’s academic background includes work on "Smallville," a project where AI agents simulated human-like behaviors in detailed virtual worlds. Simile’s ambitious goal is to eventually simulate the behaviors of all eight billion people on Earth to provide highly accurate market insights.

The startup's approach is emerging in a growing space where synthetic data and simulated user research are gaining attention from investors. By generating realistic user interactions, Simile aims to optimize product development and marketing strategies without relying solely on unpredictable human test subjects. This concept is comparable to other AI startups such as Aaru, which also raised significant funding for synthetic research solutions.

Despite the inherent challenges in perfectly replicating human behavior, Simile’s progress and strong investor interest underscore the potential of synthetic-user technology in market research. The company's swift capital raises and high-profile backing position it as a noteworthy player among AI-focused startups advancing innovative tools for businesses to understand consumer dynamics better.